IJU case reports · 2025
Granulocyte colony-stimulating factor-associated aortitis in a man with advanced prostate cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ikadai Ryota, Kitano Goshi, Kato Manabu, Kojima Takahiro
Аннотация
INTRODUCTION: Granulocyte colony-stimulating factor-associated aortitis remains poorly understood among clinicians.
CASE PRESENTATION: We present a case of G-CSF-associated aortitis in a 70-year-old male with stage IVb castration-resistant prostate cancer (cT3bN0M1b) receiving docetaxel chemotherapy. Neutropenia (280/μL) developed on day 8 of the first chemotherapy cycle, prompting subcutaneous administration of filgrastim, a short-acting G-CSF, on days 8-10. On day 14, the patient presented to the outpatient clinic with fever but no other significant symptoms. Computed tomography revealed filgrastim-induced thoracic aortitis. Daily prednisone treatment (equivalent to 25 mg prednisolone) was initiated on the following day. Although the initial episode of aortitis resolved within 5 weeks, subsequent pegfilgrastim resulted in recurrence around the left subclavian artery, necessitating further steroid therapy.
CONCLUSION: Persistent high fever following G-CSF administration may indicate drug-induced aortitis, highlighting the potential for aortitis recurrence with repeated G-CSF use.
CASE PRESENTATION: We present a case of G-CSF-associated aortitis in a 70-year-old male with stage IVb castration-resistant prostate cancer (cT3bN0M1b) receiving docetaxel chemotherapy. Neutropenia (280/μL) developed on day 8 of the first chemotherapy cycle, prompting subcutaneous administration of filgrastim, a short-acting G-CSF, on days 8-10. On day 14, the patient presented to the outpatient clinic with fever but no other significant symptoms. Computed tomography revealed filgrastim-induced thoracic aortitis. Daily prednisone treatment (equivalent to 25 mg prednisolone) was initiated on the following day. Although the initial episode of aortitis resolved within 5 weeks, subsequent pegfilgrastim resulted in recurrence around the left subclavian artery, necessitating further steroid therapy.
CONCLUSION: Persistent high fever following G-CSF administration may indicate drug-induced aortitis, highlighting the potential for aortitis recurrence with repeated G-CSF use.